Editor-in-Chief - Orthogate

Editor-in-Chief

Editor-in-Chief 's Latest Stories

Details: Category: Arthritis; Jan 30, 2013

Condition : Osteoarthritis Grade I and II (Kellgren-Lawrence Scale) Intervention : Procedure: Intra-articular injection of PRP Sponsor : Hospital Universitario Dr. Jose E. Gonzalez Recruiting - verifi...

Details: Category: Arthritis; Jan 17, 2013

Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Active, not recruiting - verified November 2013

Details: Category: Arthritis; Jan 17, 2013

Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsor : Hoffmann-La Roche Active, not recruiting - verified February 2014

Details: Category: Arthritis; Jan 17, 2013

Condition : Rheumatoid Arthritis Intervention : Drug: tocilizumab [RoActemra/Actemra] Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Recruiting - verified September 2013

Details: Category: Arthritis; Jan 16, 2013

Condition : Rheumatoid Arthritis Intervention : Sponsors : Hoffmann-La Roche; Hoffmann-La Roche Recruiting - verified September 2013

Details: Category: Arthritis; Jan 16, 2013

Condition : Rheumatoid Arthritis Intervention : Sponsor : Hoffmann-La Roche Recruiting - verified November 2013

Details: Category: Arthritis; Jan 16, 2013

Condition : Rheumatoid Arthritis Intervention : Sponsor : Hoffmann-La Roche Recruiting - verified February 2014

Details: Category: Arthritis; Jan 14, 2013

Conditions : Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis Intervention : Sponsors : AbbVie; Raffeiner GmbH; BIOCONSULT GmbH Active, not recruiting - verified February 2014

Details: Category: Arthritis; Jan 11, 2013

Condition : Rheumatoid Arthritis Interventions : Drug: sarilumab SAR153191 (REGN88); Drug: tocilizumab Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting - verified February 2014

Details: Category: Arthritis; Jan 11, 2013

Condition : Rheumatoid Arthritis Interventions : Drug: sarilumab SAR153191 (REGN88); Drug: tocilizumab Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting - verified November 2013

Page 32 of 684

The independent gateway for the orthopaedic community. Connecting professionals and patients since 1999.

Author listing

Editor-in-Chief 's Latest Stories

In Vivo and in Vitro Evaluation of PRP Therapy

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients`Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

OG Professionals

Updates

Exchange Forum

Author listing

Editor-in-Chief 's Latest Stories

TPL_FOLLOW_US

OG Professionals

Updates

Exchange Forum